Dendrites 20synapses
Moleculera logo cmyk

Moleculera Labs, Inc.

A neuroimmunology diagnostics company focused on changing how medicine is practiced for neuropsychiatric and behavioral disorders

  • Stage Full Product Ready
  • Industry Healthcare Services
  • Location Oklahoma City, OK, USA
  • Currency USD
  • Founded September 2011
  • Employees 15
  • Incorporation Type C-corp
  • Website

Company Summary

Over 60MM Americans suffer from neuropsychiatric and developmental disorders and are treated with neuropsychiatric drugs, often with little improvement. We identify patients whose symptoms are triggered by an immune dysfunction. When properly diagnosed and treated they have remarkable recoveries. Disorders include PANDAS/PANS, autism, ADD/ADHD, anxiety disorder and others. We generated over $6MM in cumulative revenue on a $5MM investment.


  • Shimasaki 20headshot 20v2
    President & CEO

    33 years biotechnology industry experience beginning at Genentech; serial entrepreneur co-founding 9 companies in molecular testing, diagnostic/medical device and therapeutics, led 5 products through FDA 510(k), taking several companies public. PhD in Molecular Biology and Biotechnology, MBA from Northwestern University’s Kellogg School of Business.

  • 45+ years experience in corporate finance and accounting, Began career at Touche Ross & Co. in 1962. Controller at Elgin National & Columbia Pictures, CFO at Wilkinson Sword, Financial consultant to numerous companies including two biotechnology companies including one publicly traded biotechnology company.

  • E82b7f43 1cbf 4a44 b570 4db9cf3738c2
    Chief Scientific Officer

    OUHSC George Lynn Cross Research Professor, over 40 years research in molecular mimicry and immunity, inventor of technology. Over 100+ peer-reviewed publications in high impact journals such as Nature Medicine, Journal of Immunology, Journal of Clinical Microbiology, Neuropsychopharmacology.

  • 9a9d0147 5adb 4854 aff3 dc2140df989b
    VP of Research & Clinical Development (Consultant)

    30+ years experience in building successful diagnostic and therapeutic companies from company inception through successful exits, including a $230M exit to Roche. Ph.D. in Biochemistry from Oklahoma State University and postdoctoral training at Dartmouth Medical School.

  • B9a4e6bf 3a5b 4d2e b453 ca3f7d3f06f9
    VP of Commercial Development (Consultant)

    30 years life science product commercialization in start-ups, a mid-cap and 3 Fortune 500 companies. Management of marketing and sales teams for Johnson & Johnson, Abbott Diagnostics and Cordis Cardiology. Directed marketing Becton Dickinson’s $210M molecular diagnostics business.


Previous Investors

  • Default avatar
    Innovation to Enterprise (i2E)
    Default avatar
    SeedStep Angels and Local Investors
    Default avatar
    Dr. Brian Clevinger, Prolog Ventures
    Managing Director
  • Default avatar
    Dr. Robert Calcaterra